Alzheimer’s disease- Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019

A new market study, titled “Alzheimer’s disease – Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019”, has been featured on WiseGuyReports.


Alzheimer’s disease Market

Alzheimer’s disease is the most common cause of dementia and increases in prevalence exponentially with age, with trends in the United States likely to worsen in ensuing decades. 
The economic burden of Alzheimer’s disease is quite high including direct and indirect costs. Indirect costs are the most important costs in early and community-dwelling AD patients. Direct costs increase when the disorder progresses, and the patient is institutionalized, or a formal caregiver is required.


Opportunities:
 
In AD, the prevalence rate doubles every 5 years and various epidemiological studies have shown the exponential growth of prevalence rate with age, starting from around 1.5-2.5% in the 65-69-year bracket, reaching almost 40% in the 90-94 year age group.1,2 In addition, according to the World Health Organization (WHO) the proportion of people over 65 years is set to increase from 6.8% in 2000 to 16.2% by 2050. Consequently, the prevalence of dementia in 2005 (24 million) is expected to rise to 81 million by 2040, assuming no changes in incidence, mortality and current preventive or curative treatments for these disorders. 

Request Free Sample Report at https://www.wiseguyreports.com/sample-request/3640366-alzheimer-s-disease-competitive-landscape-and-market-market

Scope of the report: 
Adroit Healthcare Sciences “Alzheimer’s disease – Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019” contains: 
1. Report has covered the current treatment landscape, detailed description of the drugs, pricing and market access aspects 
2. The current report contains detailed description, mechanism of action, technology, collaborations of the pipeline products. The report contains detailed description based on different phases, types and method of administration 
3. The report contains pipeline products that are in the various stages of the development including Phase 3, Phase 2, Phase 1, preclinical and discovery stage 
4. The report contains dormant and discontinued products

Why to buy: 
The report provides a comprehensive overview of the current treatment landscape, unmet needs and expectations from the future therapies. 
The report helps our clients in making key business decisions with respect to investment 
With a comprehensive report contains the different products and companies involved, it helps in identifying the commercial opportunities 

Table of Content:
Disease Overview 
Epidemiology 
Current Treatment landscape 
Unmet needs 
Currently approved products 
• Axura 
• Ebixa 
• Exelon 
• Memantine Merz 
• Prometax 
• Rivastigmine 1 A Pharma 
• Rivastigmine Hexal 
• Rivastigmine SandozFrance : HTA analysis 
Germany: HTA analysis 
United Kingdom: HTA analysis 
Italy: HTA analysis 
United States: HTA analysis 
An Overview of Pipeline 
Therapeutics under Development by companies 
Late stage products 
Mid stage products 
Early stage products 
Comparative Analysis 
Therapeutic Assessmet 
Assessment by Phase 
Dormant Products 
Discontinued Products 
Appendix 
Methodology 
About Adroit Healthcare Services 
Contact Us 
Disclaimer

View Detailed Report at
https://www.wiseguyreports.com/reports/3640366-alzheimer-s-disease-competitive-landscape-and-market-market

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.    

Tags: , , , , , , , See Website: https://www.wiseguyreports.com/sample-request/3640366-alzheimer-s-disease-competitive-landscape-and-
Contact Information:
NORAH TRENT
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)


Tags:
Research Newswire, English

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.